Dynamic Technology Lab Private Ltd acquired a new position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 63,519 shares of the biopharmaceutical company’s stock, valued at approximately $953,000. Dynamic Technology Lab Private Ltd owned approximately 0.08% of Sangamo Therapeutics at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parametric Portfolio Associates LLC acquired a new stake in Sangamo Therapeutics during the 1st quarter worth $578,000. American International Group Inc. lifted its position in Sangamo Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 42,747 shares of the biopharmaceutical company’s stock valued at $222,000 after acquiring an additional 2,818 shares in the last quarter. Teachers Advisors LLC lifted its position in Sangamo Therapeutics by 9.8% in the 1st quarter. Teachers Advisors LLC now owns 180,858 shares of the biopharmaceutical company’s stock valued at $940,000 after acquiring an additional 16,130 shares in the last quarter. Vanguard Group Inc. lifted its position in Sangamo Therapeutics by 8.4% in the 1st quarter. Vanguard Group Inc. now owns 3,087,650 shares of the biopharmaceutical company’s stock valued at $16,056,000 after acquiring an additional 239,544 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Sangamo Therapeutics by 3.1% in the 1st quarter. Geode Capital Management LLC now owns 633,964 shares of the biopharmaceutical company’s stock valued at $3,296,000 after acquiring an additional 19,331 shares in the last quarter. 64.35% of the stock is owned by institutional investors.
In other Sangamo Therapeutics news, Director Saira Ramasastry sold 5,000 shares of the firm’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $14.67, for a total value of $73,350.00. Following the completion of the sale, the director now directly owns 5,000 shares in the company, valued at $73,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William R. Ringo sold 31,000 shares of the firm’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $14.37, for a total transaction of $445,470.00. Following the completion of the sale, the director now owns 31,800 shares of the company’s stock, valued at $456,966. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 79,433 shares of company stock valued at $1,228,266. 5.50% of the stock is currently owned by corporate insiders.
Several brokerages have commented on SGMO. Barclays began coverage on shares of Sangamo Therapeutics in a research report on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 price target on the stock. Jefferies Group restated a “buy” rating and set a $18.00 price objective on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Wedbush restated a “hold” rating and set a $6.00 price objective on shares of Sangamo Therapeutics in a research note on Wednesday, November 15th. Wells Fargo & Company reiterated an “outperform” rating and issued a $30.00 price target (up previously from $20.00) on shares of Sangamo Therapeutics in a research note on Tuesday, September 5th. Finally, Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Wednesday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $17.83.
Shares of Sangamo Therapeutics, Inc. (SGMO) traded up $0.85 during midday trading on Thursday, reaching $17.20. 1,471,462 shares of the company’s stock traded hands, compared to its average volume of 1,315,498. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.02. Sangamo Therapeutics, Inc. has a 1 year low of $2.65 and a 1 year high of $18.40.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The firm had revenue of $11.81 million during the quarter, compared to analysts’ expectations of $10.37 million. During the same period in the prior year, the company posted ($0.27) EPS. The company’s revenue was up 333.0% on a year-over-year basis. research analysts expect that Sangamo Therapeutics, Inc. will post -0.73 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/07/dynamic-technology-lab-private-ltd-buys-shares-of-63519-sangamo-therapeutics-inc-sgmo.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.